GLP-1 for men: what works, what to expect. - Reddit

How do GLP-1 agonists work?

GLP-1 (glucagon-like peptide-1) is an incretin hormone released by intestinal L-cells in response to food intake. It signals the pancreas to release insulin in a glucose-dependent fashion, suppresses glucagon, slows gastric emptying, and — critically for weight management — crosses the blood-brain barrier to reduce appetite signaling in the hypothalamus.

Pharmacological GLP-1 receptor agonists amplify this signal at doses that produce sustained appetite suppression beyond what endogenous GLP-1 achieves. Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, which appears to produce additive effects on weight reduction. Neither is FDA-approved in compounded form; compounded versions are prepared by licensed 503A pharmacies under individual clinician prescriptions.

Compounded semaglutide and tirzepatide are not FDA-approved drugs. They are compounded in the USA by licensed 503A pharmacies — no hidden overseas supply chain. Every PepScribe prescription goes through clinician review before any compound is prepared.

How much weight do men lose on GLP-1?

Clinical trials on semaglutide and tirzepatide enrolled both male and female participants. In the STEP 1 trial, semaglutide 2.4 mg weekly produced a mean weight loss of approximately 15% of starting body weight over 68 weeks. In SURMOUNT-1, tirzepatide at the highest dose produced mean reductions exceeding 20% in some analyses.

Men in these trials generally had similar or slightly higher absolute weight loss in kilograms compared to women, partly driven by higher starting weights. The percentage loss was broadly comparable. Visceral fat — which is disproportionately elevated in men with central obesity — appears particularly responsive to GLP-1-class drugs, which is metabolically significant beyond the scale number.

Will GLP-1 cause muscle loss in men?

The most common concern men raise about GLP-1 therapy is muscle loss. It is a legitimate concern and deserves a direct answer.

Weight loss always includes some lean mass loss. Studies examining body composition during semaglutide treatment found that roughly 30–40% of total weight loss came from lean mass, with the remainder from fat. This ratio is broadly similar to what is observed with other caloric-restriction protocols and is not unique to GLP-1 agonists.

What this means practically: a man who loses 30 lbs on semaglutide may lose 9–12 lbs of lean mass if he does nothing else. That is a clinically meaningful amount of muscle for men who are already athletic or close to their target weight.

The two levers that reliably reduce lean mass loss during weight loss are resistance training and protein intake. Men using GLP-1 protocols who maintain resistance training and target 0.7–1 g of protein per pound of bodyweight typically fare substantially better on muscle preservation than sedentary patients at the same caloric deficit. A clinician can advise on how to structure this alongside the pharmacological protocol.

Can GLP-1 improve testosterone levels in men?

Obesity and testosterone deficiency are closely linked in men. Adipose tissue — especially visceral fat — expresses aromatase, an enzyme that converts testosterone into estrogen. Higher body fat means more aromatization and lower circulating testosterone. This can produce a self-reinforcing cycle: low testosterone reduces lean mass and motivation to exercise, which supports further fat gain.

Weight loss via any mechanism tends to improve testosterone levels in hypogonadal men with excess adiposity. Several studies have confirmed this effect with GLP-1-class weight loss, with meaningful improvements in total testosterone in men who lose significant body weight. This is not a guaranteed outcome, and the degree of improvement depends on how much of the hypogonadism is driven by adiposity versus primary testicular or pituitary dysfunction.

For men with confirmed hypogonadism who also have excess weight, clinician evaluation may reveal whether GLP-1 therapy alone is appropriate, whether testosterone replacement therapy (TRT) should be considered independently, or whether a combined approach makes clinical sense. These are not mutually exclusive.

Metabolic benefits beyond body weight

GLP-1 agonists were originally developed in the context of type 2 diabetes management, where their glucose-lowering effects and cardiovascular risk reduction in high-risk populations were the primary endpoints. Men who are not diabetic but carry central obesity often have elevated fasting glucose, insulin resistance, dyslipidemia, and elevated blood pressure — a cluster sometimes called metabolic syndrome.

GLP-1 therapy can improve several of these markers alongside weight loss. Fasting glucose typically improves, lipids often improve (LDL and triglycerides), and blood pressure may decrease modestly. Whether these improvements are driven by weight loss alone or by direct drug effects is still being studied; for clinical purposes, the composite benefit is what matters.

Framing note: PepScribe’s GLP-1 programs are positioned as weight management, not diabetes treatment. If you are managing type 2 diabetes alongside weight goals, that context belongs in your health history when you speak with a clinician — it affects protocol design and monitoring.

What side effects do men commonly report?

GI effects — nausea, reduced appetite, occasional vomiting or diarrhea — are the most commonly reported side effects across all patient populations, including men. These effects are typically most pronounced during dose escalation and tend to attenuate as the body adjusts. A slow titration schedule, which a clinician will build into your protocol, minimizes severity for most patients.

Other reported effects in some patients include fatigue during the early weeks, constipation (counterintuitively alongside the GI effects), and reduced interest in alcohol. Some men find the appetite reduction extends to social eating scenarios that previously revolved around alcohol, which can have complex lifestyle implications.

Pancreatitis is a rare but documented risk. A personal or family history of pancreatitis or medullary thyroid carcinoma requires clinician review before starting any GLP-1 protocol. This is not a general warning to avoid the drug — it is a specific contraindication that should surface in your intake.

What a GLP-1 protocol looks like through PepScribe

A clinician-supervised GLP-1 protocol starts with a review of your health history, current medications, and goals. Contraindications and risk factors are assessed. If the protocol is appropriate, you receive a prescription for compounded semaglutide or tirzepatide, prepared in the USA by a licensed 503A pharmacy — not an overseas supplier.

Dose titration is structured to minimize GI side effects. Follow-up check-ins allow the clinician to adjust your dose based on tolerance and progress. You are not handed a vial and left alone.

You can start your assessment and reach a clinician from the semaglutide or tirzepatide pages, or go directly to intake below.

Frequently asked questions